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Abstract—This study addresses the modeling of transdermal
diffusion of drugs to better understand the permeation of
molecules through the skin, especially the stratum corneum,
which forms the main permeation barrier to percutaneous
permeation. In order to ensure reproducibility and predict-
ability of drug permeation through the skin and into the
body, a quantitative understanding of the permeation barrier
properties of the stratum corneum (SC) is crucial. We
propose a multiscale framework of modeling the multicom-
ponent transdermal diffusion of molecules. The problem is
divided into subproblems of increasing length scale: micro-
scopic, mesoscopic, and macroscopic. First, the microscopic
diffusion coefﬁcient in the lipid bilayers of the SC is found
through molecular dynamics (MD) simulations. Then, a
homogenization procedure is performed over a model unit
cell of the heterogeneous SC, resulting in effective diffusion
parameters. These effective parameters are the macroscopic
diffusion coefﬁcients for the homogeneous medium that is
‘‘equivalent’’ to the heterogeneous SC, and thus can be used
in ﬁnite element simulations of the macroscopic diffusion
process. The resulting drug ﬂux through the skin shows very
reasonable agreement to experimental data.
Keywords—Fentanyl, Permeation enhancer, Oleic acid,
Multiscale, Molecular dynamics, Homogenization, Finite
element method.
INTRODUCTION
Throughout the past three decades, the transdermal
patch has become a proven technology that oﬀers
signiﬁcant clinical beneﬁts over other dosage forms.
Compared to the more conventional oral dosing, sys-
temic delivery of drugs by percutaneous permeation
oﬀers several advantages such as avoidance of pre-
systemic metabolism in the gastrointestinal tract and
liver, a controlled drug release rate that can provide
relatively constant concentrations of drug in the
circulation for several days, and improved patient
compliance. Although transdermal patches have been
marketed for about 25 years, only around 10 diﬀerent
compounds, all of them with molecular weights
<500 amu, are currently delivered transdermally. A
major obstacle to the wider application of this delivery
route is the low skin permeability of many drugs,
which prevents administration of eﬀective doses from
patches of acceptable physical dimensions.
The transdermal drug delivery system consists of the
delivery device (the patch) and the various layers of the
skin. The goal is to deliver the drug from the patch
through the intervening skin layers to the microvas-
culature underneath. The parts of the skin that are of
main interest in transdermal delivery are the upper-
most stratum corneum and underlying layers of the
viable epidermis. The stratum corneum has been
identiﬁed as providing the primary barrier against
permeation of compounds through the skin. It consists
of two phases with very diﬀerent characteristics—
tightly packed keratinized cells (corneocytes) sur-
rounded by the intercellular lipid matrix. The impli-
cations of the biphasic structure of the stratum
corneum on its transport properties have been
explored previously.30,33 For most compounds that are
soluble in oil, the primary transport pathway seems to
be the intercellular lipid matrix.23
One way of increasing the permeation of drugs in
the skin is by including permeation enhancers in
the transdermal delivery formulation. Permeation
enhancers facilitate permeation of penetrants through
the skin by temporarily diminishing the barrier prop-
erties of the skin.32,33 Ideally, these materials should be
pharmacologically inert, nontoxic, and nonirritating,
and the skin should immediately regain its barrier
properties on its removal. Various classes of perme-
ation enhancers and their mechanisms of action have
been reviewed by Sinha and Kaur.38 The mechanisms
by which enhancers affect skin permeability have been
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described as: disruption of the intercellular bilayer lipid
structure; interaction with the intracellular proteins of
the stratum corneum; and improvement of partitioning
of a drug into the stratum corneum.4
For development and optimization of eﬀective
transdermal formulations, it is important to under-
stand the mechanism of drug permeation from the
delivery device across the skin. During the last two
decades, many researchers have studied percutaneous
absorption of drugs both experimentally and theoret-
ically. Both transport through the device and through
the skin are generally considered to follow Fickian
diﬀusion through a simple homogeneous membrane.
The studies on transport of compounds through the
skin may be divided into two large categories: those
that deal with the skin as a whole11,25,26,34 and those
that concentrate on the stratum corneum as a separate
layer.11,18,27,30 Here, we take the second approach, by
explicitly considering the biphasic microstructure of
the stratum corneum.
Among studies that have explored the implications
of the biphasic structure of a medium on its transport
properties, several have estimated the lipid pathway
tortuosity and the eﬀective diﬀusivity of the stratum
corneum,23,26,30,41 while others have focused on diffu-
sion across artiﬁcial barrier membranes.13,16 Several
were 2-D studies of the cross-sections of the stratum
corneum (or membrane), estimating the macroscopic
diffusivity in the trans-membrane direction from geo-
metric arguments,23 Monte-Carlo calculations16 or by
measuring the pathlength directly from micrographs.41
For the 3-D structure, the method of asymptotic
expansions was used to ﬁnd the effective diffusivity for
both impermeable and permeable corneocytes.35,36
The thinness and fragility of the stratum corneum
layer make it diﬃcult to measure its permeability di-
rectly. In addition, experimentally measured perme-
abilities oﬀer scant information regarding the diﬀerent
contributions to the observed values, namely the
interaction of the drug with its environment in the
skin, and the heterogeneous structure of the stratum
corneum. Therefore, the eﬀect of designing a drug with
a diﬀerent chemical moiety, or the eﬀects of adding
permeation enhancers that act on the lipid and cor-
neocytes of the stratum corneum diﬀerently cannot be
readily inferred. On the other hand, the heterogeneity
of the microstructure is a challenge for numerical
determination of the permeability and necessitates a
multiscale approach. The method should be able to
account in a consistent manner for both the diﬀusion
of substances in their molecular-level environment and
the microstructure of the stratum, and be capable of
considering enhancement of the permeability by a
second (or third) component. Toward this goal, a
hierarchical multiscale framework of modeling the
transdermal diﬀusion of molecules is presented in this
study. We start by using molecular dynamics (MD)
simulations to calculate the microscopic diﬀusion
coeﬃcient in the lipid bilayers of the SC. MD simula-
tions of the drug fentanyl in a lipid/cholesterol system
that is close in character to the SC lipid are performed,
and the molecular diﬀusivities of fentanyl are calcu-
lated from the resulting trajectories. Oleic acid, a
chemical enhancer, is added to the model where it
aﬀects the diﬀusion characteristics of the fentanyl
molecules.
In the next step, a homogenization procedure is
performed over an idealized unit cell of the heteroge-
neous SC, resulting in eﬀective diﬀusion parameters.
The method of asymptotic expansions is used to obtain
the macroscopic diﬀusion tensor for the stratum cor-
neum. The eﬀective diﬀusivity tensors are calculated
for the case of coupled multi-component diﬀusion of
drugs diﬀusing along with permeation enhancers.
These eﬀective parameters are the macroscopic diﬀu-
sion coeﬃcients for the homogeneous medium that is
‘‘equivalent’’ to the heterogeneous SC.
In the ﬁnal step, ﬁnite element modeling of the
macroscopic diﬀusion problem together with the
eﬀective diﬀusion coeﬃcients results in the quantiﬁca-
tion of drug ﬂux delivered through the skin.
The next three sections describe each of the micro-,
meso-, and macroscale problems. The resulting drug
ﬂux through the skin shows very reasonable agreement
to experimental data.
MICROSCOPIC DIFFUSION OF FENTANYL
IN A LIPID BILAYER
The model drug is fentanyl (C22H28N2O) (Fig. 1). It
is a synthetic opioid 75–100 times more potent than
that of morphine. It was the ﬁrst analgesic available for
transdermal administration, with a low molecular
weight of 336.5 amu and octanol-water partition
FIGURE 1. Chemical structure of fentanyl.
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coefﬁcient of about 800. In addition, studies of the
bioavailability of fentanyl delivered transdermally
found that 92% of the administered dose reached the
systemic circulation, with no signiﬁcant cutaneous
metabolism or degradation.42 The pharmacological
and pharmacokinetic properties of transdermal fenta-
nyl along with its therapeutic efﬁcacy have been
extensively reviewed.19,21
The stratum corneum lipid composition is highly
complex; in our approach, the stratum corneum lipids
are modeled by a bilayer composed of dimyristoyl-
phosphatidylcholine (dmpc)-cholesterol with 50 mol%
cholesterol. It has been shown experimentally that the
diﬀusion coeﬃcients in the dmpc-cholesterol lipids
correspond well to those in the stratum corneum lip-
ids.22 Figure 2 shows the dmpc-cholesterol bilayer with
a fentanyl molecule in the center of the bilayer.
Permeation enhancers are an important part of
many transdermal drug delivery formulations. The
enhancers diﬀuse along with the drug and increase
the permeability of the drug by temporarily altering the
skin barrier (primarily the stratum corneum). One
example is oleic acid, which increases drug partitioning
and drug permeation in the skin. Oleic acid molecules
were added to the fentanyl-dmpc-cholesterol systems
in order to study the eﬀect of oleic acid on the lipid
bilayer and the diﬀusivity of fentanyl.
The diﬀusion coeﬃcient of fentanyl molecules
within the lipid membranes can be obtained from the








r tþ t0ð Þ  r t0ð Þð Þ2
D E
; ð1Þ
where s is the number of spatial dimensions, r(t) is the
center-of-mass (COM) coordinates at time t.39 The
average Æ æ is taken over all initial times t0.
The transport of small molecules through lipid
bilayer membranes is central to many biological pro-
cesses, such as passive drug and metabolite uptake.
Since the early 1990s molecular dynamics studies of
diﬀusion of small molecules in lipid bilayers have been
extensively pursued.2,5,6,29 These studies have shown
that small solutes diffuse at different rates depending
on their location in the bilayer, with high diffusion
rates found in the center of the bilayer, where the
membrane density is low, while much lower diffusion
rates were found in the region of the headgroups. In
order to get a more detailed description of the posi-
tion-dependence of the diffusion process, a series of
simulations of dipalmitoylphosphatidylcholine (dppc)
and dmpc lipids systems were performed with a single
fentanyl molecule and different numbers of oleic acid
molecules, where the fentanyl molecule is constrained
in the z-direction (normal to the bilayer) to certain
depths in the bilayer, while still being free to move in
the xy plane.
The lateral diﬀusivity of fentanyl as a function of
the depth of the bilayer can be found from Eq. (1).
The mean-square displacements were calculated for
the center-of-mass position of each fentanyl molecule
and averaged over time. In order to correct for the
relative bilayer leaﬂet motions, the center-of-mass
coordinates of each fentanyl molecule was corrected
by subtracting the center-of-mass coordinates of the
lipid leaﬂet. The time origin was shifted every 10 ps
for better statistics.
HOMOGENIZATION OF THE BIPHASIC
STRUCTURE OF THE STRATUM
CORNEUM—MULTICOMPONENT
COUPLED DIFFUSION
The main geometric features of the stratum cor-
neum are the corneocytes and the lipid bilayers. The
FIGURE 2. Molecular dynamics unit-cell of dmpc-cholesterol
bilayer with a fentanyl molecule in the center of the bilayer.
The bilayer is solvated by water molecules. For clarity, the
fentanyl molecule is depicted with larger atoms. Colors of
atoms are: H (white), C (green), O (red), N (blue).
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diﬀusion of drug through the stratum corneum
involves not only the molecular diﬀusion of the drug in
the corneocytes and the lipid bilayers, but also depends
on the details of the three dimensional arrangement of
the two phases. The length scale of the heterogeneity is
on the order of the size of the corneocytes—about
40 lm wide and 1 lm thick—and is much smaller than
the typical diameter of several centimeters of the
stratum corneum of interest in transdermal drug
delivery. The addition of permeation enhancers results
in a coupled multi-component diﬀusion system. In this
section, we expand the development of our previous
work35,36 by considering the homogenization of a
system of equations describing coupled two-compo-
nent diffusion, where the diffusivity of one component
(drug) is a function of the concentration of the other
component (enhancer).
Consider the domain X of the stratum corneum
such that X ¼ Xcor [ Xlip; where Xcor and Xlip are the
corneocyte and lipid regions, respectively (see Fig. 3).
The problem is governed by Fickian diffusion in X and
expressed by




Dabij x; c1; c2ð Þ
@cb x; tð Þ
@xj
 
¼ 0; in X
ð2Þ
for the components a = 1, 2, with appropriate
boundary conditions. Summation is implied over the
spatial indices i, j ranging from 1 to the number of
spatial dimensions (3 for 3-D or 2 for 2-D), and the
component index b where b = 1, 2, and will be the case
in the following as well, unless indicated otherwise.
The following development is for the 3-D case, but it is
a simple matter to modify it for the 2-D problem. The
diffusivities Dij
ab are now functions both of position and
concentration, and assume different functional forms
depending on whether the position x falls in the cor-
neocytes or in the lipid matrix,
Dabij x; c1; c2ð Þ ¼
Dabij
 cor
c1; c2ð Þ x 2 Xcor
Dabij
 lip





We assume the distribution of the corneocytes in the
stratum corneum is periodic, characterized by a small
parameter e, so that the diﬀusivities in Eq. (2) depend
on e, and are of the form
Dabij
 e







ab’s are periodic functions of a reference
period R. The size of the periodic unit cell of the
structure is denoted by e > 0. The periodic model of
the stratum corneum structure with a unit cell Y is
shown in Fig. 3. For simplicity, we will follow the
standard assumption of the corneocytes being imper-
meable. This has been well established in the case of
lipophilic drugs, for which the main transport pathway
is the intercellular lipid matrix.23 In other words,
Dij
cor = 0, and Eq. (2) becomes










in Y \ Xlip ð5aÞ
 Dabij
 e
x; c1; c2ð Þ @cb x; tð Þ
@xj
ni ¼ 0; on Y \ C ð5bÞ
for a = 1, 2, and C denotes the boundary between the
corneocytes and the lipid phase. ni is the ith component
of the unit normal vector on C. However, in the case of
hydrophilic compounds an extension to permeable
corneocytes could be easily made, parallel to the
development for the single component diffusion.36
FIGURE 3. (a) Cross-sectional view of the stratum corneum
and the unit cell Y. The grey areas denote the corneocytes,
while the white indicate the intercellular lipid matrix; (b) a
micrograph of a cross-section of the human stratum corneum,
with a unit cell corresponding to that in (a). Reproduced from
Talreha et al.41
RIM et al.1220
Writing the solution as ca x; y; tð Þ ¼ cð0Þa x; y; tð Þþ
ecð1Þa x; y; tð Þ þ e2cð2Þa x; y; tð Þ þ    ; and expanding Dijab(y,
c1, c2) using Taylor’s expansion, with (y, c1
(0), c2
(0)) as the








































for a = 1, 2, and where r ¼ RY\Xlip dy
R
Y dy is the
volume fraction available for diffusion, or the porosity
of the stratum corneum (barrier membrane), and the
functions vbk’s are Y-periodic functions with b = 1, 2
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vakdy ¼ 0; ð8cÞ
where djk is the Kronecker delta function.
We postulate a simple linear relationship for the
diﬀusivities, where the diﬀusivities of the drug (com-
ponent 1) are linear functions of the enhancer con-
centration (component 2), while the diﬀusivity of the
enhancer itself is constant. This assumption is valid
for the range of concentrations being considered, as
shown by the MD results (see the section ‘‘Results’’).
The arrangement of lipid bilayers within the stratum
corneum is not understood in full detail. In the face
of this uncertainty we take the simplest approach and
assume the lipid phase to be isotropic. Therefore
Dij
ab = Dabdij, and all the cross-diffusivities are taken
to be zero.
D11ii y; c1; c2ð Þ ¼ D11
 0þ D11 1c2; i ¼ 1; 2; 3:
D22ii y; c1; c2ð Þ ¼ D22
 0
; i ¼ 1; 2; 3:
Dabij y; c1; c2ð Þ ¼ 0; i 6¼ j or a 6¼ b
ð9Þ
where (D11)0, (D11)1, (D22)0 are constants. Both the
spatial and interspecies cross-diffusivities are taken to
be zero.
From Eq. (7), note that the linear relationship in the





























In essence, the eﬀective diﬀusion coeﬃcients are
obtained by multiplying the molecular diﬀusion coef-
ﬁcients (Daa)0 in the lipids by the factor Sjk
a .
THE TRANSDERMAL DIFFUSION
OF FENTANYL WITH OLEIC ACID
AS PERMEATION ENHANCER
The macroscopic model system consists of a thin
layer of adhesive patch that is loaded with the drug
and enhancer, the stratum corneum layer, and the
underlying viable epidermis layer. The viable epidermis
is considered as a single homogeneous phase. In fact, a
considerable amount of evidence indicates that it is a
permeable phase that functions as a viscous aqueous
layer tomost permeants.17 A sink boundary condition is
applied to the lower surface of the viable epidermis,
modeling the perfect uptake of the drug and enhancers
by the microcapillaries. The diffusion domain X is then
composed of three cylindrical layers, the dermal patch
(subdomainXA), the stratum corneum (subdomainXB),
and the viable epidermis (subdomainXC). The patch is a
single-layer adhesive in which the drug fentanyl (com-
ponent 1, with concentration c1) and enhancer oleic acid
(component 2, with concentration c2) are uniformly
dissolved initially. A side view of the system along with
its dimensions is shown in Fig. 4. The radius of the skin
is set to be large enough so that the ﬂux of the compo-
nents across the sides of the skin domain is negligible.
Also, we assume that no drug or permeation enhancer
transport occurs through the top or the sides of the
dermal patch, therefore simple zero ﬂux boundary
conditions are speciﬁed at these boundaries.
The system of equations describing the diﬀusion in









¼ 0 inXa0;T½; ð11aÞ
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nai ¼ 0 on Cah 0;T½; ð11cÞ
where the indices l, m = 1, 2, indicate the concentra-
tion component and i = 1, … ,nsd, are the spatial
indices for the number of spatial dimensions nsd.
Dlmij
 a
is the ijth component of the diffusivity tensor
that relates a ﬂux of component l occurring due to a
concentration gradient of component m in material a.
Cg is the lower surface of the viable epidermis with the
sink boundary condition and Ch
a denotes the side and
top surfaces of the domain where no ﬂux conditions
are applied. ni
a indicates the ith (spatial) component of
the vector normal to the boundary.
At the interfaces between the subdomains CI, there
is an interface ﬂux of each chemical species which must
satisfy the following conditions that impose the con-








nbi ¼ kl on CbI0;T½; ð12bÞ
where a and b are adjacent subdomains that share the
interface CI: the superscript on CI serves as a reminder
of the domain to which CI is considered to belong for
each equation. kl is the normal interface ﬂux of com-
ponent l, and the opposite signs on kl indicates the fact
that the ﬂux ﬂowing out of one subdomain must ﬂow
into the other to maintain mass conservation. Sum-
mation is implied over the chemical species index m
and the spatial indices i and j.
In addition to the preceding sets of equations, a
condition describing the partitioning of each species
across the interface is needed. The partitioning results
in a discontinuity in the concentration of each chemical













for m = 1, 2, where Km
a describes the equilibrium dis-
tribution of component m in material a, relative to a
common reference material. Since only the ratio of
Kam

Kbm is relevant, the reference material can be taken
to be any arbitrary material.
The formulation of the ﬁnite element equations and
matrices of Eqs. (11)–(13) is essentially the same as in
Rim et al.,35 except that the diffusivities are no longer
isotropic, and there is a retardation factor n in the ﬁrst
term. The presence of n poses no difﬁculty as it is
simply incorporated into the mass matrix.
The parameters needed to solve the problem are the
retardation factors, diﬀusivities, and partition coeﬃ-
cients of the drug and enhancer in the three subdo-
mains. The patch and the viable epidermis are
considered to be isotropic, and since the lateral diﬀu-
sivities in the stratum corneum are equal, the problem
can be formulated as an axisymmetric one.
COMPUTATIONAL METHODS
Molecular Dynamics
The united-atom dmpc force ﬁeld was taken from
the dppc force ﬁeld of Berger et al.9 for the most part,
with six charge groups for the headgroup.3 The mod-
iﬁcations are described below. For the water, we used
the simple point-charge (SPC) model.7 The united-
atom force ﬁeld for cholesterol is taken from the work
of Ho¨ltje et al.20 and is based on the GROMACS
ffgmx force ﬁeld. Oleic acid has a single hydrocarbon
chain; the double bonded hydrocarbon parameters
along with the parameters for the –COOH group were
taken from the ffgmx force ﬁeld.
For the fentanyl molecule, the minimum energy
structure was calculated with Gaussian98 (Gaussian
Inc., Wallingford, CT, USA), using the 6-31G(d) basis.
The minimum energy structure is very similar to the
crystal structure of the citrate–toluene solvate of fen-
tanyl (CSD refcode: PEPCIT10) with the only signiﬁ-
cant diﬀerence being the dihedral angle of the bond
between the benzene ring and the CH3 group. The
bond lengths, bond angles, and dihedral angles of the
fentanyl minimum energy structure and those of the
crystal structure are for the most part very close to
each other, and also to the corresponding parameter
values of the ffgmx force ﬁeld. For those bond lengths,
bond angles, or the dihedral angles of the fentanyl
structure that differed from the equilibrium values of
the ffgmx force ﬁeld by >5%, and the parameter
values for the bond lengths, bond angles, or the dihe-
dral angles that do not exist in the ffgmx force ﬁeld, the
equilibrium values were taken to be those from the









FIGURE 4. The macroscopic diffusion domain and its
dimensions. The domain consists of the transdermal patch
(A), the stratum corneum (B), and the epidermis (C) layers.
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The force constants for the bond stretching, angle
bending, and dihedral torsion interactions were taken
from the ﬀgmx force ﬁeld as were the Lennard–Jones
parameters. For those interactions that were not
deﬁned in the ﬀgmx force ﬁeld, we took the force
constants of the interaction that most closely
corresponded to the atom types involved in the
interaction.
The partial atomic charges of fentanyl were calcu-
lated using the Gaussian98 program. The CHELPG
charges of fentanyl were derived with the 6-31G(d)
basis and based on the minimum energy conﬁguration
of the molecule. The charges for the united-atom
approximation were then derived by combining the
charges of hydrogen atoms into the attached carbon
atom. The charges on the benzene rings were further
adjusted by redistributing the charges so that the
symmetry of the benzene ring is preserved.
Two sets of simulations were performed, with and
without the enhancer oleic acid. The bilayers consist of
32 dmpc and 32 cholesterol molecules arranged in a
bilayer form and fully hydrated with water molecules.
The bilayers were equilibrated for 4 ns. For the simu-
lations with oleic acid, 12 and 24 molecules of oleic
acid were inserted at random positions in the dmpc-
cholesterol systems, in equal numbers in each leaﬂet,
and equilibrated for 4 ns each. A fentanyl molecule
was inserted at the center of the dmpc-cholesterol and
dmpc-cholesterol-oleic acid bilayers, and pulled in the
+z and z directions using the pull code of Gromacs
3.2.18,28 with a pull rate of 0.001 nm/ps, relative to the
center of the bilayer. For every 0.2 nm, the fentanyl
molecule is constrained in the z-coordinate, while the
lateral displacements are collected for four simulations
of 1 ns length each, for a total of 4 ns. The constraint
on the fentanyl molecule is applied through resetting
the z-coordinate of the center-of-mass position of the
fentanyl molecule at every time step to the reference
depth relative to the center-of-mass of the lipid mole-
cules.
For the electrostatic interactions, the particle mesh
Ewald (PME) method was used. The Lennard–Jones
interactions were cutoﬀ at a distance of 1 nm. The
constant temperature and pressure of 310 K and 1 atm
were maintained through the Berendsen weak coupling
schemes, with coupling times of 0.1 and 1 ps, respec-
tively. All bond lengths of the lipid molecules were
kept constant using the LINCS routine, and the water
geometry was maintained with the SETTLE algorithm.
The time step for integration was taken to be 2 fs. The
simulations were performed with the molecular
dynamics package GROMACS version 3.2.18,28 on the
Silicon Graphics Orgin 3800 shared memory super-
computer, courtesy of the Center for Biomedical
Computing at Stanford University.
Homogenization
As described in the section ‘‘Homogenization of the
biphasic structure of the stratum corneum—multi-
component coupled diffusion,’’ the effective diffusivi-
ties of the stratum corneum are found by a method of
homogenization which uses the molecular diffusivities,
extracted according to the methods of the sec-
tion ‘‘Molecular dynamics,’’ in the ‘‘cell problem,’’
equation (8). The cell problem is solved using the ﬁnite
element method as follows.
The meshes were created using MSC Patran (MSC
Software, Santa Ana, CA, USA). The 2-D meshes
consist of 450 to 490 rectangular 4-node elements with
4 integration points per element for numerical quad-
rature. The 3-D meshes have 8680 to 8950 8-node brick
elements with 8 integration points per element. Sepa-
rate meshes had to be created for each geometric
conﬁguration, and the element sizes were kept as
consistent as possible. A ﬁnite element code that we
developed was used, with a sparse gaussian elimination
solver SuperLU_MT.14 To test the convergence of the
meshes, a 2-D mesh was created with 1168 4-node
elements. The relative difference in the results was on
the order of 104, indicating convergence.
Finite Element Method
The mesh of the domain consists of 1230 4-node
rectangular elements with 4 integration points per
element, and 1442 nodes. The mesh was again created
with MSC Patran. The time integration and iterative
algorithms are as described in Rim et al.35
RESULTS
Molecular Diﬀusivity of Fentanyl in a Lipid Bilayer
The lateral diﬀusivities of fentanyl in dmpc-choles-
terol and dmpc-cholesterol-oleic acid bilayers as a
function of position in the bilayer are shown in Fig. 5.
The lateral diffusion proﬁles are characteristic of solute
diffusion in lipids—faster diffusion in the center of the
bilayer and much slower diffusion in the dense head-
group region. The average lateral diffusivity of fenta-
nyl in the dmpc-cholesterol bilayer is (1.2 ± 0.4) 9
107 cm2/s. The average was taken over the inner 2 nm
of the bilayer, since for lateral movement it is most
likely that the molecule will stay in the tail region of
the bilayer. When oleic acid is included in the system,
the diffusivity of fentanyl is increased—mostly in the
center of the bilayer. The average diffusivity of fenta-
nyl was found to be (2.17 ± 0.6) 9 107 and
(3.97 ± 1.1) 9 107 cm2/s for the systems with 12 and
24 oleic acid molecules, respectively. The oleic acid
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concentrations of the two systems calculated from the
volume of the bilayers are 0.065 and 0.13 g/cm3. From
these the following linear relationship between the
oleic acid concentration and the average lateral diffu-
sivity of fentanyl may be deduced,
Dlat ¼ 2:03 106coleic þ 1:2 107
¼ 1:2 107 16:7coleic þ 1ð Þ;
with R2 = 0.965.
The lateral diﬀusion of oleic acid molecules on the
other hand was found to be independent of the oleic
acid concentration. The oleic acid molecules have an
average lateral diﬀusivity of (2.65 ± 0.9) 9 108 cm2/s
in the dmpc-cholesterol bilayer.
Eﬀective Diﬀusivity of Fentanyl in a Homogeneous
Stratum Corneum
The corneocytes are modeled as square tiles, with
edge length 40 lm and thickness 0.8 lm. The hori-
zontal and vertical gaps between the corneocytes which
are occupied by the lipid matrix are taken to be 75 nm.
The layers of corneocytes cells are stacked so that
successive layers are displaced by exactly half the
corneocyte edge length in the horizontal directions.
These geometric parameters were taken from Johnson
et al.23 for air-dried (partially hydrated) stratum cor-
neum.
For the above geometry, solving Eqs. (8a)–(8c) for
the functions vak and using those function values to














¼ 0:0006 D11 0þ D11 1cð0Þ2
 
;
D^2211 ¼ D^2222 ¼ 0:0876 D22
 0
;
D^2233 ¼ 0:0006 D22
 0
;
and all the other diﬀusivity terms are zero.
Finite Element Modeling of Transdermal Diﬀusion
of Fentanyl
The retardation factor diﬀers from unity only in the
stratum corneum, where it is equal to the porosity of
0.0891. The diﬀusivity of fentanyl in the patchwas taken
from experimental studies to be 1.0 9 109 cm2/s.34
Preliminary calculations indicated that the diffusivity of
oleic acid in the patch does not affect the results sig-
niﬁcantly, and therefore it was assumed to be equal to
the diffusivity of fentanyl. The lateral and transverse
diffusivities of fentanyl without any oleic acid in the
stratum corneum were found through molecular
dynamics simulations and homogenization to be
1.05 9 108 and 7.2 9 1011 cm2/s, respectively. The
lateral and transverse diffusivities of oleic acid in the
stratum corneum were similarly found to be 2.32 9
109 and 1.59 9 1011 cm2/s. Oleic acid was found to
increase the diffusivities of fentanyl as a linear function
of oleic acid concentration, with constants of propor-
tionality of 1.78 9 107 and 1.22 9 109 cm5/(g s), for
the lateral and transverse diffusivities. The diffusivity of
oleic acid was found to be unaffected by the concen-
tration. Data on diffusivities of compounds in the viable
epidermis are unfortunately very rare, and are not
available for fentanyl and oleic acid. Chandrasekaran
et al.11 measured the diffusivity of scopolamine
(C17H21NO4) in delipidized epidermis, and found a va-
lue of 2.0 9 107 cm2/s. Since scopolamine has a
molecular weight of 303.4, comparable to those of fen-
tanyl (336.5) and oleic acid (282.5), we chose to adopt
the diffusivity of scopolamine for the diffusivities of
fentanyl and oleic acid in the viable epidermis layer. The
lateral and transverse diffusivities of fentanyl and oleic
acid are tabulated in Table 1. The values of transverse
diffusivities for both fentanyl and oleic acid are well
within the range of experimental diffusivities for the
stratum corneum of 109 to 1012 cm2/s.37
The partitioning of drug and enhancer between the
patch and the stratum corneum, and between the
stratum corneum and the viable epidermis, are
important determinants of the transdermal permeation
process. The partitioning coeﬃcient of fentanyl from
the patch into the stratum corneum has been estimated
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FIGURE 5. Lateral diffusivities of fentanyl in dmpc-choles-
terol (filled) and dmpc-cholesterol-oleic acid (open) bilayers
as functions of depth.
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acid are lipophilic molecules, and the same value is
assumed for the partitioning of oleic acid into the
stratum corneum. For partitioning between the stra-
tum corneum and the viable epidermis, taking into
account the aqueous nature of the viable epidermis, the
partition coefﬁcients of both fentanyl and oleic acid are
approximated by the empirical formula given by
Johnson et al.,23
KSC=aq ¼ K0:76o=w;
where KSC/aq is the partition coefﬁcient between the
stratum corneum and an aqueous phase, and Ko/w is
the octanol-water partition coefﬁcient. From the val-
ues of the octanol-water partition coefﬁcients for fen-
tanyl and oleic acid, which are estimated to be 860 and
5 9 107, respectively, the partition coefﬁcients between
the stratum corneum and the epidermis are 0.006 and
1.41 9 106 for fentanyl and oleic acid, respectively.
The initial concentration of fentanyl in the patch
was 0.09 g/cm3. The macroscopic diffusion problem
was solved for three different initial concentrations of
oleic acid in the patch: 0, 0.13, and 0.25 g/cm3. The
concentration of fentanyl and oleic acid in the patch,
the stratum corneum and the epidermis layers at time
t = 10 h are shown as a function of depth (in the
center of the domain) in Fig. 6. Note that the increase
in fentanyl diffusivity in the stratum corneum due to
the enhancer results in the concentration proﬁles
crossing in Fig. 6b. The concentrations at the inter-
faces between subdomains are discontinuous due to
partitioning.
The ﬂux of fentanyl crossing the lower boundary
(Cg) of the domain is shown in Fig. 7a as functions of
time. The ﬂux of fentanyl when the stratum corneum
layer is omitted is shown in Fig. 7b. The experimental
fentanyl ﬂux from a transdermal patch through human





















































FIGURE 6. Concentration profiles of fentanyl in the (a) patch; (b) stratum corneum; and (c) viable epidermis as a function of depth
from the top surface of the patch at t 5 10 h. (diamonds 5 no oleic acid, squares 5 initial oleic acid concentration in
patch 5 0.13 g/cm3, triangles 5 initial oleic acid concentration in patch 5 0.25 g/cm3).
TABLE 1. Diffusivities of fentanyl and oleic acid in the
different layers of the diffusion domain.
D11 = D22 D33
Fentanyl
Patch 1.0 9 109 1.0 9 109
Stratum corneum 1.78 9 107 c2 +
1.05 9 108
1.22 9 109 c2 +
7.2 9 1011
Viable epidermis 2.0 9 107 2.0 9 107
Oleic acid
Patch 1.0 9 109 1.0 9 109
Stratum corneum 2.32 9 109 1.59 9 1011
Viable epidermis 2.0 9 107 2.0 9 107
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shown in Fig. 7c.34 Details on the experimental setup is
included in the supplementary material.
DISCUSSION
The lateral diﬀusivities of small compounds have
been measured by ﬂuorescence recovery after photo-
bleaching (FRAP) to be in the range of 6 9 108 to
1.6 9 107 cm2/s in pure dmpc bilayers and
2–5.6 9 108 cm2/s in dmpc-cholesterol bilayers at
300 K.1,22 The average lateral diffusivity of fentanyl in
the model lipid system of (1.2 ± 0.4) 9 107 cm2/s is
on the same order as the experimental data, the dif-
ference may be attributed to some or all of the fol-
lowing: differences in the liphophilicity and shape
factor of the molecules considered and the concentra-
tion of the molecules in the bilayer.
The eﬀect of oleic acid on the bilayer is to increase
both its cross-sectional area and the disorder of the
lipid tails. These may largely be due to the kink in the
unsaturated hydrocarbon tail of oleic acid that needs
to be accommodated, consistent with the observation
that unsaturated fatty acids are more eﬀective in
enhancing transdermal permeation of drugs than
saturated fatty acids.12 These changes in the bilayer
structure act to increase the diffusivity of the fentanyl
molecule, proportional to the amount of oleic acid
present in the bilayer. The oleic acid itself has a much
smaller diffusivity, in agreement with the observation
that oleic acid, once introduced, remains in the skin for
a prolonged period of time. The oleic acid concentra-
tion does not seem to affect its own diffusivity, though
this may be due to the small concentrations of oleic
acid present in the simulations. The lateral diffusivity
of oleic acid in the bilayer is on the same order as that
of the lipid molecules, which implies that oleic acid,
which is a fatty acid, is easily incorporated into the
lipid bilayer and effectively becomes a component of
the bilayer itself.
In this work, we assumed that the main mechanism
for permeation through the lipid bilayers in the stra-
tum corneum is lateral diﬀusion. This is contrary to
considerations of drug molecules crossing the plasma
membrane, where the trans-bilayer diﬀusion is the
primary transport mechanism. One reason for this is
that lateral diﬀusion is faster than transbilayer diﬀu-
sion by a factor of up to nine orders of magnitude.23 In
addition, although the organization of lipid bilayers in
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FIGURE 7. (a) Fentanyl flux through the lower boundary of the viable epidermis for different initial concentration of oleic acid in the
patch; (b) fentanyl flux through the lower boundary of the viable epidermis when the stratum corneum is removed; (c) experimental
fentanyl flux through human skin; for details see the supplementary information.
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assumption would be that the lipid bilayers are con-
tinuous throughout the stratum corneum, with defects
and interconnections between the individual bilayers
that allow solute to traverse the entire stratum cor-
neum by lateral diffusion alone.23,43 In fact, electron
microscope (EM) studies of the stratum corneum have
shown that adjacent bilayers often merge together,
such that solutes can diffuse from one bilayer to an-
other by lateral diffusion.15,40 Note that in the limit of
a large enough number of interconnections between
the bilayers, the lipid can justiﬁably be considered
isotropic as in (10).
For molecules for which the corneocytes are
impermeable, the eﬀective diﬀusivity in the stratum
corneum is a measure of the tortuosity of the diﬀusion
path. The large diﬀerence of two orders of magnitude
between the in-plane and transverse eﬀective diﬀusiv-
ities reﬂects the diﬀerent tortuosities of the diﬀusion
path in each direction. The horizontally elongated
shape of the corneocytes acts to hinder the diﬀusion
mainly in the trans-stratum corneum direction, and
therefore eﬀectively contributes to the permeation
barrier properties of the skin.
The stratum corneum with its high resistance to
diﬀusion acts as the rate-regulating membrane in the
transdermal system. The small partitioning coeﬃcient
of fentanyl between the stratum corneum and viable
epidermis also plays an important role in slowing down
the rate of permeation. The small diﬀusivity of fentanyl
in the stratum corneum acts to keep the ﬂux at a fairly
constant level for longer periods, which is desirable in
transdermal delivery systems. The role of the stratum
corneum as the rate-regulating layer can be seen more
clearly in Fig. 7b. Without the stratum corneum layer,
the ﬂux of fentanyl shows an initial sharp peak fol-
lowed by a rapid decrease. Although the stratum cor-
neum can easily be removed, the result of removing the
permeation barrier is not simply that of increased drug
ﬂux which may be beneﬁcial, but also a sharp variation
in the ﬂux with time that is undesirable.
The peak fentanyl ﬂux of about 1.3 lg/(cm2 s)
through the diffusion domain is smaller than, but
comparable to the experimental value of about 2.5 lg/
(cm2 s) as in Fig. 7c.34 The larger experimental values
can be explained by the fact that the skin samples were
stored fully hydrated before the experiments were
conducted. The hydration level of the skin and sub-
sequent swelling of the corneocytes was shown to result
in signiﬁcant increases in the effective diffusivity
through the stratum corneum.35 In particular, experi-
mental studies both in vitro and in vivo suggest that
hydration can increase ﬂux up to twofold. In view of
this fact, the agreement between the calculations and
the experiments seems quite promising, especially
considering that many approximations and assumptions
were made over the different length scales. Another
factor to be addressed is the discrepancy in the
ﬂux-time proﬁle between the numerical and experi-
mental data. This suggests that the parameters values
are not correct, in view of the fact that the calculated
ﬂux peaks earlier and remains much steadier than the
experimental data indicates that the diffusion coefﬁ-
cient might be too large, and partition coefﬁcient too
low. In addition, some of the parameters such as the
partitioning coefﬁcients would be time dependent due
to a change in environment. Systematic parametric
studies would cast light upon these questions; further
exploration of these issues are beyond the scope of the
current work.
The addition of oleic acid increases the ﬂux of the
fentanyl appreciably. In addition, the small diﬀusion
coeﬃcient of oleic acid in the stratum corneum leads to
the change in shape of the ﬂux curves with the addition
of oleic acid in Fig. 7a. The ﬂux reaches its maximum
value at a later time when oleic acid is added to the
system. This is due to the slow diffusion of the oleic
acid in the stratum corneum; the enhancement effect
increases with time as the oleic acid lingers and builds
up in the stratum corneum. This changes the ‘‘steadi-
ness’’ of drug delivery: the length of time where the ﬂux
is within 10% of the peak value decreases from 40 to
30 to 27 h as the oleic acid concentration is increased
from 0 to 0.25 to 0.5 g/cm3. The addition of oleic acid
increases the rate of delivery, but at the cost of
decreasing the effective time period of each patch.
A main drawback of the method is the dependence
on experimental results, which may not be readily
available for other molecules. Another limitation is the
computational cost of the molecular dynamics simu-
lations—however, the advance of coarse-grained
membrane lipid models10 means that this can be sig-
niﬁcantly reduced.
Some uncertainties regarding the eﬀects of perme-
ation enhancers have not been addressed here. Com-
parisons of stratum corneum extracted lipids with
dmpc and dmpc-cholesterol bilayer systems have sug-
gested that liquid crystalline phase dmpc-cholesterol
bilayers would be a reasonable model of stratum cor-
neum lipids for diﬀusion coeﬃcients of solute mole-
cules22,24,31 and is further corroborated by the
agreement for the calculated and experimental fentanyl
ﬂux. However, the effects of permeation enhancers on
dmpc/cholesterol bilayer systems might be different
from their effects on stratum corneum lipids, and
experimental veriﬁcation of the degree to which oleic
acid increases fentanyl ﬂux is needed.
The two major eﬀects of adding a permeation
enhancer into a transdermal delivery formulation is an
increase in both the diﬀusion coeﬃcient of the drug in
the skin and the solubility (and therefore the partition
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coeﬃcient) of the drug in the skin. Synergy between the
two eﬀects will have a multiplicative eﬀect on the
transdermal ﬂux of the drug. However, few enhancers
have been studied in suﬃcient detail to distinguish
between these eﬀects, and in this work, we have only
considered the eﬀect on the diﬀusion coeﬃcient. In our
earlier work,34 we presented a framework for posing and
better understanding the question of the relative mag-
nitudes of these two effects, by modeling the increase in
diffusivity and partitioning independently as functions
of the enhancer concentration, this may be easily
incorporated into the current framework to explore the
effects of partition coefﬁcient more thoroughly.
CONCLUSIONS
This study presents a framework for studying the
multi-component diﬀusion of drugs coupled with
enhancers through the skin by considering the micro-
structure of the stratum corneum (SC). The diﬀerent
length scales involved in the transdermal diﬀusion
process are addressed in detail and the contribution of
each length scale is integrated into the macroscopic
permeation barrier of the stratum corneum. This is a
signiﬁcant improvement from the previous pharma-
cokinetic models or purely macroscopic continuum
studies of the transdermal diﬀusion problem. This
framework is applicable to general problems of trans-
port through heterogeneous composite media.
Areas for further investigation would include
improved and more eﬃcient lipid models, better
qualiﬁcation of the eﬀects of diﬀerent classes of per-
meation enhancers on model lipid systems, study of the
corneocytes, and a more realistic geometry of corneo-
cytes. Experimental information on partitioning and
diﬀusion properties of the lipid and corneocytes are
also very much in need.
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